LANTERN PHARMA RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING BIOMARKER-GUIDED TREATMENT WITH LP-184 (ZIRDAFULVEN) IN MULTIPLE SOLID TUMOR CANCERS

Reuters · 5d ago

Please log in to view news